J&J's COVID-19 vaccine gets final clearance, nears shipping


The federal government, through distribution partner McKesson Corp, plans to ship the first shots Sunday night or Monday morning. (File pic shows J&J vaccine vial. - Reuters

WASHINGTON: A U.S. Centers for Disease Control and Prevention advisory panel voted unanimously on Sunday to recommend Johnson & Johnson's COVID-19 shot for widespread use, a final clearance for the vaccine a day after it was authorized by U.S. regulators.

The Advisory Committee on Immunization Practices (ACIP) voted 12-0 to recommend the vaccine from J&J as appropriate for Americans 18 and older. There was one abstention due to prior conflicts of interest.

"We believe today's recommendation from the CDC to begin use of our vaccine as part of the U.S. national immunization program will add a critical tool in the fight against COVID-19," Paul Stoffels, J&J's chief scientific officer, said in a statement.

State and local public health authorities will use Food and Drug Administration (FDA) and CDC guidance as they administer the first 4 million doses. The federal government, through distribution partner McKesson Corp, plans to ship the first shots Sunday night or Monday morning

ACIP has played a major role in guiding states on how to allocate scarce doses, though states themselves have the final say in how they allocate shots.

CDC epidemiologist Dr. Sara Oliver said during a Sunday presentation that there are not yet any studies comparing J&J's vaccine directly to the other approved vaccines from Pfizer-BioNTech and Moderna Inc, but that all vaccines were highly effective at reducing hospitalizations and deaths.

Both the Pfizer and Moderna vaccines, which are based on new messenger RNA technology, showed higher efficacy rates in trials that used two doses versus J&J's single-shot vaccine. Direct comparison, however, is difficult because the trials had different goals and J&J's was conducted while more contagious new variants of the virus were circulating.

The panelists echoed remarks by officials at the FDA on Saturday, who said Americans should take whichever authorized vaccine is available to them.

Oliver also said there was insufficient data to know whether the vaccines' safety or efficacy could be compromised by pre-existing conditions that compromise a person's immune systems.

CDC Director Rochelle Walensky has approved the panel's recommendations.

Oliver added in her presentation that deploying J&J's vaccine can help ensure equitable distribution of shots to underserved communities.

J&J's shot will be the only one-dose COVID vaccine available in the United States. It is also the easiest to ship and store, as it can be kept in a refrigerator rather than a freezer.

J&J expects to ship more than 20 million doses by March and 100 million by midyear, enough to vaccinate nearly a third of Americans

- Reuters
Article type: metered
User Type: anonymous web
User Status:
Campaign ID: 46
Cxense type: free
User access status: 3
   

Next In Business News

Khazanah raises RM312mil from TM share placement
FBM KLCI ends higher despite negative broad-market breadth
Tricor apologises for Maybank AGM rescheduling
CIMB Group underlying business proves resilient in FY20 despite pandemic effects
Pertama Digital increases court bail limit to RM500k via eJamin
UMW vehicle sales up 35% in 1Q21
UOB Malaysia reiterates commitment to support country's transition to cleaner energy
Maybank to reschedule 61st AGM
LPI posts improved 1Q net profit of RM82.31mil
Press Metal, glove stocks lift FBM KLCI

Stories You'll Enjoy


Vouchers